Welcome to our dedicated page for Viridian Therapeutics news (Ticker: VRDN), a resource for investors and traders seeking the latest updates and insights on Viridian Therapeutics stock.
Viridian Therapeutics, Inc. (Nasdaq: VRDN) is a Waltham, Massachusetts-based biopharmaceutical company focused on discovering, developing, and commercializing potential best-in-class medicines for serious and rare diseases. News about Viridian often centers on its late-stage programs in thyroid eye disease (TED), regulatory milestones, clinical trial updates, and financing activities that support its pipeline and anticipated commercialization efforts.
Investors following VRDN news can expect frequent updates on veligrotug, Viridian’s intravenously delivered anti–IGF‑1R antibody for TED. Company announcements have highlighted the completion of two global phase 3 trials, THRIVE and THRIVE‑2, positive topline data, and the U.S. Food and Drug Administration’s acceptance of a Biologics License Application with Priority Review and a defined PDUFA target action date. News releases also discuss preparations for a potential commercial launch, including market access, medical affairs, and engagement with a core prescriber base.
Another key news theme is VRDN‑003 (elegrobart), a subcutaneous, half‑life extended anti‑IGF‑1R antibody in phase 3 trials REVEAL‑1 and REVEAL‑2 for active and chronic TED. Viridian’s press releases describe enrollment progress, anticipated topline data timing, and the design of VRDN‑003 for subcutaneous administration in a low‑volume autoinjector with every‑four‑week or every‑eight‑week dosing. Updates on Viridian’s FcRn inhibitor portfolio—including VRDN‑006 and VRDN‑008—cover proof‑of‑concept IgG reduction data, investigational new drug (IND) submissions, and preclinical head‑to‑head findings.
VRDN news also frequently includes corporate and financial developments, such as public equity offerings, royalty financing agreements, amended credit facilities, and collaboration and license agreements like the partnership with Kissei Pharmaceutical Co., Ltd. for veligrotug and VRDN‑003 in Japan. These disclosures provide context on how Viridian plans to fund its clinical programs and potential commercial launches. For a comprehensive view of Viridian’s evolving TED pipeline, autoimmune disease programs, and capital strategy, readers can review the ongoing stream of press releases, earnings updates, and SEC-reported events associated with the VRDN ticker.
Viridian Therapeutics (Nasdaq: VRDN) priced upsized concurrent offerings: $225.0 million aggregate principal of 1.75% convertible senior notes due 2032 and 7,352,942 shares of common stock at $17.00 per share, for aggregate gross proceeds of $350.0 million.
Viridian estimates aggregate net proceeds of approximately $334.7 million. Offerings are expected to close on May 11, 2026. Net proceeds will repay Hercules loan, fund TED market expansion studies, advance early pipeline R&D, and for working capital.
Viridian Therapeutics (Nasdaq: VRDN) announced proposed concurrent public offerings of $150.0 million aggregate principal amount of convertible senior notes due 2032 and $100.0 million of equity (common stock and Series B non-voting convertible preferred stock) on May 5, 2026. Each Series B share converts into 66.67 common shares subject to ownership limits. The offerings include 30-day 15% overallotment options for underwriters. Proceeds are intended to repay outstanding indebtedness to Hercules Capital, fund TED market expansion studies, advance earlier pipeline R&D, and for working capital. Pricing and final terms remain subject to market conditions and SEC prospectus filings.
Viridian Therapeutics (Nasdaq: VRDN) reported Q1 2026 progress including a PDUFA target date of June 30, 2026 for veligrotug and an EMA MAA accepted for review after a January 2026 submission. Elegrobart posted positive pivotal REVEAL-1 and REVEAL-2 topline data; a BLA is anticipated in Q1 2027. Cash and marketable securities were $762.2M as of March 31, 2026. VRDN-006 and VRDN-008 remain on-track for 2026 development updates and 2H 2026 phase 1 data, respectively.
Viridian Therapeutics (Nasdaq: VRDN) announced positive topline results from the REVEAL-2 phase 3 trial of subcutaneous elegrobart in chronic thyroid eye disease (TED). REVEAL-2 (n=204) met FDA and EMA primary endpoints: proptosis responder rates were 50% (Q4W) and 54% (Q8W) versus 15% placebo (p < 0.0001). Mean proptosis change: -1.9 mm (Q4W) and -2.1 mm (Q8W) vs -0.5 mm placebo. Q4W diplopia responder rate was 61% vs 38% placebo (p=0.0118). Safety was generally consistent with prior data; 91% completed treatment. BLA submission is on track for Q1 2027.
Viridian Therapeutics (Nasdaq: VRDN) reported positive topline REVEAL-1 Phase 3 results for subcutaneous elegrobart in active thyroid eye disease (TED). Q4W and Q8W arms showed proptosis responder rates of 54% and 63% versus 18% placebo at week 24. Diplopia resolved in 51% (Q4W) versus 16% placebo. Safety was generally well tolerated; low tinnitus reports. Viridian ended Q4 2025 with $875 million cash. REVEAL-2 topline is on track for Q2 2026 and a BLA is anticipated in Q1 2027.
Viridian Therapeutics (Nasdaq: VRDN) reported Q4 and full-year 2025 results and program updates. Key items: PDUFA target date June 30, 2026 for veligrotug in TED, MAA submitted to EMA in January 2026, REVEAL‑1 and REVEAL‑2 topline readouts on track in Q1 and Q2 2026, VRDN‑008 IND cleared and phase 1 started, and $874.7M cash as of December 31, 2025. The company expects existing cash, anticipated milestones, and potential commercial revenues to fund plans through profitability if lead programs are approved.
Viridian Therapeutics (Nasdaq: VRDN) announced inducement grants of non-qualified stock options covering 16,650 shares to one new employee, approved by the independent Compensation Committee on January 2, 2026. The grants were made outside the company's 2016 Equity Incentive Plan under Nasdaq Listing Rule 5635(c)(4) but remain subject to that plan's terms. Exercise price equals the closing price on the grant date. Vesting is over four years: 25% after one year, then the remainder in 36 equal monthly installments, subject to continued employment.
Viridian is a biopharmaceutical company advancing IGF-1R candidates (veligrotug with positive phase 3 THRIVE and THRIVE-2 topline results; elegrobart in ongoing REVEAL-1 and REVEAL-2 phase 3 trials) and other programs including TSHR and FcRn inhibitors.
Viridian Therapeutics (NASDAQ: VRDN) outlined 2026 priorities including a PDUFA target date of June 30, 2026 for the veligrotug BLA under Priority Review and ongoing commercial launch preparations. Topline phase 3 results for subcutaneous elegrobart (VRDN-003) are expected in Q1 2026 (REVEAL-1) and Q2 2026 (REVEAL-2). An IND for half-life extended FcRn-inhibitor VRDN-008 was submitted in December 2025 with healthy volunteer data expected in 2H 2026. A new TSHR inhibitor IND is expected in Q4 2026. Cash and investments were approximately $888 million as of October 31, 2025, and the company expects to fund current plans through profitability.
Viridian Therapeutics (NASDAQ: VRDN) announced that the FDA accepted the Biologics License Application for veligrotug to treat thyroid eye disease and granted Priority Review with a PDUFA target action date of June 30, 2026. Priority Review shortens the review timeline to six months. Veligrotug already holds Breakthrough Therapy designation. The BLA is supported by positive topline data from two global phase 3 trials (THRIVE and THRIVE-2) that met primary and all secondary endpoints, including the first phase 3 demonstration of statistically significant diplopia response and resolution in chronic TED and a rapid proptosis response. Veligrotug is a five-infusion IV course completed in 12 weeks. Viridian plans an EMA Marketing Authorization Application submission in Q1 2026.
Viridian Therapeutics (Nasdaq: VRDN) announced that its Compensation Committee approved non-qualified stock options totaling 171,900 shares as inducement grants to three new employees on Dec 1, 2025 under Nasdaq Listing Rule 5635(c)(4).
The options were granted outside the company’s 2016 Equity Incentive Plan but remain subject to its terms, have an exercise price equal to the Dec 1, 2025 closing price, and vest over four years (25% after one year, then monthly over 36 months) subject to continued employment.
The release also summarizes Viridian’s clinical programs, noting that veligrotug (VRDN-001) reported positive topline results in two global Phase 3 trials (THRIVE and THRIVE-2) and that VRDN-003 is in two ongoing global Phase 3 pivotal trials (REVEAL-1 and REVEAL-2).